drugset / Trial / NCT01072058
Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker
NaSingle-groupOpen-labelScreening
Summary
The purpose of this study is to determine possible alterations in cardiac function in patients with Rheumatoid Arthritis and Ankylosing Spondylitis under anti-TNF therapy, without clinical heart disfunction at baseline, using highly sensitive non-invasive methods.
Timeline
- Start
- 2008-02
- Primary completion
- 2011-02
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adalimumab | Monoclonal antibody | 40 mg | Subcutaneous |
| Subject | Etanercept | Protein / enzyme biologic | 50 mg | Subcutaneous |
| Subject | Infliximab | Monoclonal antibody | 3 mg/kg | — |
| Subject | Infliximab | Monoclonal antibody | 5 mg/kg | — |